Cargando…
The FDA-Approved Drug Pyrvinium Selectively Targets ER(+) Breast Cancer Cells with High INPP4B Expression
SIMPLE SUMMARY: Wnt/β-catenin signaling is hyperactivated in many human cancers including up to 50% of breast cancers. Although there has been significant progress in developing therapeutics that suppress Wnt/β-catenin signaling, particularly in colon cancer, the repurposing of FDA-approved therapeu...
Autores principales: | Rodgers, Samuel J., Ooms, Lisa M., Mitchell, Christina A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817693/ https://www.ncbi.nlm.nih.gov/pubmed/36612130 http://dx.doi.org/10.3390/cancers15010135 |
Ejemplares similares
-
Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis
por: Li, Bin, et al.
Publicado: (2014) -
The Antihelmintic Drug Pyrvinium Pamoate Targets Aggressive Breast Cancer
por: Xu, Wei, et al.
Publicado: (2013) -
Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007) -
Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020) -
Recently FDA-approved drug: A new hope for vitiligo patients?
por: Siddiq, Mohammad Arham, et al.
Publicado: (2022)